Cancerous Stem Cells Researched
Posted on: Friday, 21 December 2007, 21:00 CST
Researchers at three U.S. medical centers are testing a cancer drug under the theory that some cancers are fed by cancerous stem cells.
The researchers said cancerous stem cells are aberrant cells that maintain and propagate malignant tumors. The stem cells may be impervious to most standard cancer therapies, The New York Times said Friday.
While critics say the stem cell enthusiasts are heading down a blind alley, proponents of the theory are looking for ways to kill the stem cells, the newspaper said.
Proponents of the hypothesis say chemotherapy and radiation often destroy most of a tumor but if they do not kill the stem cells, it can grow back.
The University of Michigan Comprehensive Cancer Center, Baylor College of Medicine in Houston and the Dana-Farber Cancer Institute in Boston plan to begin testing a drug developed by Merck to treat Alzheimer's disease. It did not work on Alzheimer's but kills breast cancer stem cells in laboratory studies, the report said.
The study will start with a safety test on 30 women who have advanced breast cancer.
Source: United Press International
Related Articles
- Discovery Pinpoints New Link Between Cancer Cells, Stem Cells
- Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
- Point Therapeutics Presents Positive Results in Phase 2 Talabostat Non-Small Cell Lung Cancer Study
- STELLAR 2 and 4 Pivotal Trials Demonstrate XYOTAX(TM) Produces Equivalent Survival While Significantly Reducing Serious Side Effects in the Treatment of First- or Second-Line Non-Small Cell Lung Cancer
- The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-Small Cell Lung Cancer*
- CTI to Report Results From STELLAR 3 Pivotal Trial of XYOTAX(TM) in Non-Small Cell Lung Cancer Ahead of Previous Guidance
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
- The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-Small Cell Lung Cancer*: A Retrospective Analysis
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
- New Targets for Detection and Treatment of Small Cell Lung Cancer*
 |
 |
User Comments (0)
RSS Feeds